Healthcare ❯Pharmaceuticals

Gene Therapy

Duchenne Muscular Dystrophy FDA Regulation Hemophilia Treatment Rare Diseases

Pfizer and Merck Diverge in Q2 Performance Amid Revised Forecasts

Pfizer achieves revenue growth and raises guidance, while Merck lowers profit outlook despite strong drug sales.

FDA Approves Controversial Gene Therapy for All Duchenne Muscular Dystrophy Patients

FDA Approves Revolutionary $4.25 Million Gene Therapy for Rare Genetic Disorder